Apr 2022
Host: Professor Khaled Salama & Professor Sahika Inal
Abstract:
The
availability of technologies capable of tracking the levels of drugs,
metabolites, and biomarkers in real time in the living body would
revolutionize our understanding of health and our ability to detect and
treat disease. Imagine, for example, a dosing regimen that, rather than
relying on your watch ("take two pills twice a day"), is instead guided
by second-to-second measurements of plasma drug levels wirelessly
communicated to your smartphone. Such a technology would likewise
provide researchers and clinicians an unprecedented window into
physiology, such as neurochemistry, and could even support
ultra-high-precision personalized medicine in which drug dosing is
optimized minute-by-minute using closed-loop feedback control. Towards
this goal, we have developed a biomimetic,electrochemical sensing
platform that supports the high frequency, real-time measurement of
specific molecules (irrespective of their chemical reactivity) in situ
in the blood and tissues of awake, freely moving subjects.
Bio:
Kevin
Plaxco is a Professor at the University of California, Santa Barbara,
with appointments in the Department of Chemistry and Biochemistry, the
Department of Mechanical Engineering, the Biomolecular Science and
Engineering Graduate Program, and the Biological Engineering Graduate
Program. Prior to joining UCSB in 1998 Dr. Plaxco received his Ph.D.
from Caltech and performed postdoctoral studies at Oxford and the
University of Washington. Dr. Plaxco's research focus is on the physics
of biomolecular folding and its engineering applications. A major aim of
the group's applied research is to harness the speed and specificity of
folding in the development of sensors, adaptable surfaces, and smart
materials. Dr. Plaxco has co-authored more than 230 papers and a dozen
patents on protein folding, protein dynamics, and folding-based sensors,
and is recognized by Thomson Reuters as one of the most highly cited
chemists of the prior decade. He serves on the scientific boards of a
half dozen biotechnology firms, several of which are commercializing
technologies developed by his group, and has also written a popular
science book on Astrobiology.